NCT06506916

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

A Phase 3b Exploratory Multicenter Open-Label Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).

Conditions

• Moderate to Severe Plaque Psoriasis
• Psoriatic Arthritis

Interventions

Type	Name	Description
DRUG	bimekizumab	Study participants receive bimekizumab (BKZ) administered subcutaneously at pre-specified timepoints during study.

Timeline

• Start date: 2024-07-29
• Primary completion: 2027-03-09
• Completion: 2028-03-14
• First posted: 2024-07-18
• Last updated: 2026-02-27

Locations

16 sites across 3 countries: United States, Germany, Poland

Regulatory

• FDA-regulated drug study